Drug intelligence / Profile preview

Hexavalent norovirus vaccine (Grand Theravac Life Sciences)

Development stage: Unknown
Lead developer: Grand Theravac Life Science Nanjing
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The hexavalent norovirus vaccine is a recombinant virus-like particle (VLP) vaccine developed by Grand Theravac Life Sciences (Nanjing) Co., Ltd. for the prevention of norovirus-induced acute gastroenteritis. Produced using the *Hansenula polymorpha* (Hansen yeast) expression system, the vaccine consists of VLPs that mimic the structure of six different norovirus strains/genotypes but lack viral genetic material, rendering them non-infectious. By targeting multiple genotypes, the vaccine aims to provide broad protective immunity against the genetically diverse norovirus strains responsible for global outbreaks. It has progressed to Phase 2 clinical development following safety and immunogenicity evaluations in Phase 1 trials involving participants aged 6 months and older.

Other names: Recombinant hexavalent norovirus VLP vaccineHexavalent norovirus vaccine

Targets

NV (Norovirus)

Beyond the preview

Go deeper on Hexavalent norovirus vaccine (Grand Theravac Life Sciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexavalent norovirus vaccine (Grand Theravac Life Sciences).

Explore the full profile